A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy (Q28287088)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy	scientific article

Statements

scholarly article

0 references

A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy (English)

0 references

colorectal cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

metastatic colon cancer

1 reference

based on heuristic

inferred from title

colorectal carcinoma

1 reference

based on heuristic

inferred from title

author name string

W Zhang

1

0 references

T Winder

2

0 references

Y Ning

3

0 references

A Pohl

4

0 references

D Yang

5

0 references

M Kahn

6

0 references

G Lurje

7

0 references

M J Labonte

8

0 references

P M Wilson

9

0 references

M A Gordon

10

0 references

S Hu-Lieskovan

11

0 references

D J Mauro

12

0 references

C Langer

13

0 references

E K Rowinsky

14

0 references

H-J Lenz

15

0 references

language of work or name

0 references

publication date

January 2011

0 references

Annals of Oncology

0 references

22

0 references

1

0 references

104-9

0 references

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ315

21 January 2018

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ315

21 January 2018

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ315

21 January 2018

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ315

21 January 2018

Cetuximab for the treatment of colorectal cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ315

21 January 2018

EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ315

21 January 2018

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ315

21 January 2018

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ315

21 January 2018

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ315

21 January 2018

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ315

21 January 2018

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ315

21 January 2018

Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ315

21 January 2018

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ315

21 January 2018

Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ315

21 January 2018

Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ315

21 January 2018

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ315

21 January 2018

Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ315

21 January 2018

FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ315

21 January 2018

Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ315

21 January 2018

MicroRNA polymorphisms: the future of pharmacogenomics, molecular epidemiology and individualized medicine

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ315

21 January 2018

MicroRNA target site polymorphisms and human disease

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ315

21 January 2018

RAS is regulated by the let-7 microRNA family

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ315

21 January 2018

A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ315

21 January 2018

A let-7 microRNA-binding site polymorphism in the KRAS 3' UTR is associated with reduced survival in oral cancers

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ315

21 January 2018

Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ315

21 January 2018

let-7 microRNA functions as a potential growth suppressor in human colon cancer cells

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ315

21 January 2018

EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ315

21 January 2018

Identifiers

10.1093/ANNONC/MDQ315

0 references

release_zhdqcbsburawpkf3os6wi2obsq

1 reference

https://api.fatcat.wiki/v0/release/zhdqcbsburawpkf3os6wi2obsq

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

https://api.fatcat.wiki/v0/release/zhdqcbsburawpkf3os6wi2obsq

24 November 2022

based on heuristic

mapped directly with Wikidata item

0 references

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28287088&oldid=1843576707"